No Data
Is NextCure (NASDAQ:NXTC) In A Good Position To Deliver On Growth Plans?
NextCure Price Target Maintained With a $4.00/Share by Needham
Piper Sandler Maintains NextCure(NXTC.US) With Buy Rating, Maintains Target Price $3
Piper Sandler analyst Edward Tenthoff maintains $NextCure(NXTC.US)$ with a buy rating, and maintains the target price at $3.According to TipRanks data, the analyst has a success rate of 35.8% and a
Piper Sandler Keeps Their Buy Rating on NextCure (NXTC)
Needham Maintains NextCure(NXTC.US) With Buy Rating, Maintains Target Price $4
Needham analyst Gil Blum maintains $NextCure(NXTC.US)$ with a buy rating, and maintains the target price at $4.According to TipRanks data, the analyst has a success rate of 41.4% and a total average
Buy Rating for NextCure Supported by Promising Clinical Results and Strong Financial Position